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Summary
Background Observational studies report that higher intake of dietary ﬁ bre (a heterogeneous mix including non-
starch polysaccharides and resistant starches) is associated with reduced risk of colorectal cancer, but no randomised 
trials with prevention of colorectal cancer as a primary endpoint have been done. We assessed the eﬀ ect of resistant 
starch on the incidence of colorectal cancer. 
Methods In the CAPP2 study, individuals with Lynch syndrome were randomly assigned in a two-by-two factorial 
design to receive 600 mg aspirin or aspirin placebo or 30 g resistant starch or starch placebo, for up to 4 years. 
Randomisation was done with a block size of 16. Post-intervention, patients entered into double-blind follow-up; 
participants and investigators were masked to treatment allocation. The primary endpoint for this analysis was 
development of colorectal cancer in participants randomly assigned to resistant starch or resistant-starch placebo with 
both intention-to-treat and per-protocol analyses. This study is registered, ISRCTN 59521990.
Findings 463 patients were randomly assigned to receive resistant starch and 455 to receive resistant-starch placebo. 
At a median follow-up 52·7 months (IQR 28·9–78·4), 53 participants developed 61 primary colorectal cancers (27 of 
463 participants randomly assigned to resistant starch, 26 of 455 participants assigned to resistant-starch placebo). 
Intention-to-treat analysis of time to ﬁ rst colorectal cancer showed a hazard ratio (HR) of 1·40 (95% CI 0·78–2·56; 
p=0·26) and Poisson regression accounting for multiple primary events gave an incidence rate ratio (IRR) of 1·15 
(95% CI 0·66–2·00; p=0·61). For those completing 2 years of intervention, per-protocol analysis yielded a HR of 1·09 
(0·55–2·19, p=0·80) and an IRR of 0·98 (0·51–1·88, p=0·95). No information on adverse events was gathered during 
post-intervention follow-up.
Interpretation Resistant starch had no detectable eﬀ ect on cancer development in carriers of hereditary colorectal 
cancer. Dietary supplementation with resistant starch does not emulate the apparently protective eﬀ ect of diets rich in 
dietary ﬁ bre against colorectal cancer. 
Funding European Union, Cancer Research UK, Bayer Corporation, National Starch and Chemical Co, UK Medical 
Research Council, Newcastle Hospitals Trustees, Cancer Council of Victoria Australia, THRIPP South Africa, The 
Finnish Cancer Foundation, SIAK Switzerland, and Bayer Pharma.
Introduction 
The incidence of colorectal cancer rises steeply with age 
and risk is aﬀ ected strongly by environmental factors 
including adiposity, physical activity, and habitual diet.1 A 
systematic review of the epidemiological literature shows 
convincing evidence that higher intakes of red meat, 
processed meat, alcoholic drinks (men only), and 
increases in body fat increase the risk of colorectal cancer, 
whereas greater physical activity reduces risk. 
Additionally, the evidence was assessed as probable that 
alcoholic drinks (women only) increase risk whereas 
foods containing dietary ﬁ bre and garlic, milk, and 
calcium reduce risk of colorectal cancer.1 A recent meta-
analysis of 21 prospective studies showed a signiﬁ cant, 
dose-dependent protective eﬀ ect of dietary ﬁ bre intake 
against colorectal cancer (relative risk [RR] per 10 g a day 
increase in dietary ﬁ bre intake 0·90, 95% CI 0·86–0·94).2 
Dietary ﬁ bre is a food-based measure that attempts to 
estimate the heterogeneous mix of carbohydrates (non-
starch polysaccharides, starches, and oligosaccharides) 
that escape digestion in the small bowel and ﬂ ow to the 
large bowel where they exert a wide range of physiological 
eﬀ ects due, in part, to the bacterial fermentation of these 
carbohydrates to yield biologically active short-chain fatty 
acids.3 An inverse association exists between starch 
intake and risk of colorectal cancer,4 which could be due 
to resistant starch (ie, the dietary starch and starch 
degradation products that escape digestion in the small 
intestine of healthy individuals).5 Resistant starch 
reduced colonic neoplasia in several carcinogen-treated 
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rat studies6,7 but high intakes of this starch increased 
intestinal tumorigenesis in the genetically driven 
Apc1638N mouse model.8 The antineoplastic eﬀ ect of 
resistant starch is believed to result largely from the 
fermentation endproducts short-chain fatty acids and, in 
particular, butyrate.9,10 In addition to inhibition of tumour-
cell proliferation, butyrate might reduce risk of colorectal 
cancer by enhancing the apoptotic response to DNA 
damage.7,11–13 Preliminary evidence shows that butyrate 
might have more potent antineoplastic eﬀ ects on colon 
cancer cells with dysfunction of the DNA mismatch 
repair gene MLH1.14
Few studies of the eﬀ ects of resistant starch on 
colorectal carcinogenesis in human beings have been 
done and most have used putative biomarkers of 
colorectal-cancer risk as endpoints. Early studies showed 
that resistant-starch feeding for short periods (typically 
4 weeks) reduced faecal excretion of cytotoxic secondary 
bile acids15,16 and in some, but not all, studies reduced 
mucosal-cell proliferation.16 Short-term (2–4 weeks) 
supplementation with resistant starch in 65 patients with 
colorectal cancer signiﬁ cantly reduced (p=0·028) the 
proportion of mitotic cells in the top half of the colonic 
crypt and produced diﬀ erential eﬀ ects on expression of 
key cell-cycle regulatory genes (CDK4 and GADD45A) in 
tumour tissue.17 The duration of resistant-starch feeding 
required to provoke changes in biomarkers of colorectal-
cancer risk is not known but is probably greater than 
1 week.18 In the Colorectal Adenoma/carcinoma 
Prevention Programme (CAPP) 1 study in young people 
with familial adenomatous polyposis, supplementation 
with resistant starch (1:1 blend of raw potato starch and 
high amylose maize starch [Hylon V11]) for a median 
intervention period of 17 months reduced crypt length 
and cell proliferation but no eﬀ ect was detected on polyp 
count in the rectum and sigmoid colon (RR 1·05, 95% CI 
0·73–1·49).19
Lynch syndrome (also known as hereditary non-
polyposis colon cancer) is the most common monogenic 
predisposition to colorectal cancer with most patients 
carrying pathological DNA mismatch repair gene 
variants. In the CAPP2 study done over 6 years, 
937 people with Lynch syndrome from 43 international 
centres commenced intervention with aspirin, resistant 
starch, or both in a two-by-two factorial design.20,21 After 
intervention (mean 29 months [SD 13·7]) there was no 
evidence that either agent inﬂ uenced development of 
colonic neoplasia with most lesions being adenomas.20 
However, the original design of the CAPP2 study 
included double-blind post-intervention follow-up for 
at least 10 years and a recent analysis (mean 
55·5 months [SD 31·1]), showed that 600 mg aspirin a 
day for a mean of 25 months [13·4]) halved cancer 
incidence in carriers of hereditary colorectal cancer.21 
We assessed the eﬀ ect of resistant starch on the 
incidence of colorectal cancer, the primary CAPP2 
outcome, and on other Lynch syndrome cancers as 
secondary outcomes. The baseline population diﬀ ers 
from our ﬁ rst report, which was conﬁ ned to those with 
an exit colonoscopy.20 
Methods 
Trial design and participants
Details of the design and conduct of the CAPP2 study 
have been previously published.20,21 Recruitment was 
from January, 1999, to March, 2005. Participants were 
required to have a proven germline mutation in a 
mismatch repair gene or a personal and family medical 
history commensurate with a diagnosis of Lynch 
syndrome. 83% of all participants had a proven germline 
mutation.
Ethics committee approval was obtained from all 
centres from which participants were recruited.
Randomisation and masking
In this two-by-two factorial trial, randomisation was 
undertaken centrally by DTB with the SAS (version 6) 
uniform random number generator to randomise each 
participant separately for aspirin and for starch.20,21 We 
used block randomisation by geographical region so that 
after 16 randomisations four patients were in each of the 
four treatment combinations. Masking to treatment 
allocation was done with coded packaging, which did not 
reveal the nature of the contents (intervention or placebo). 
Procedures
Patients who were randomly assigned to receive resistant 
starch were given Novelose 240 and Novelose 330 
(National Starch and Chemical Company, Bridgewater, 
NJ, USA) in one-to-one blend daily with recommended 
administration in two separate doses, while those 
assigned to receive resistant-starch placebo were given 
Amioca waxy starch daily with recommended 
administration as per resistant starch to maintain 
masking, for up to 4 years. Novelose 240 and Novelose 330 
are fermented in the large bowel to increase 
concentrations of butyrate and other short-chain fatty 
acids.22 The additional digestible starch in the placebo 
(30 g a day) is nutritionally unimportant compared with 
typical dietary intakes of 150–350 g a day.23 
The period of intervention lasted a mean of 29 months 
(median 25·3 months [IQR 23·7–33·5]) at which point 
we reported eﬀ ects of the interventions (aspirin and 
resistant starch) on colorectal neoplasia (most lesions 
being adenomas).20 The original design of the CAPP2 
study included double-blind post-intervention follow-up 
for at least 10 years to investigate eﬀ ects on cancer risk. 
All CAPP2 participants were under regular colonic 
surveillance organised through their local clinical 
genetics service. Predominantly follow-up was via the 
routine annual surveillance. A few centres followed up 
every 2 years. The genetic centres were asked to return 
information on cancer history to the CAPP2 oﬃ  ce after 
these routine examinations. Follow-up continued as long 
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as possible; this analysis reﬂ ects the most recent follow-
up data available from all participants. 
The current analysis focuses on the follow-up of those 
participants randomly assigned to resistant starch or 
resistant-starch placebo who started the CAPP2 study from 
their date of entry into CAPP2 until the last known date for 
which the local clinical centre had information about their 
status regarding cancer diagnosis. However, in most cases, 
this timepoint corresponded with the date of last 
attendance at the clinic responsible for their surveillance. 
In this analysis, we included (1) patients with Lynch 
syndrome cancers, which were recorded in the earlier 
report;20 (2) all cancers that occurred in patients for whom 
an exit colonoscopy was not recorded in the initial report, 
thus excluding them from the statistical analysis in our 
ﬁ rst report;20 and (3) cancers that occurred subsequent to 
exit from the intervention phase. No information on 
adverse events was gathered during post-intervention 
follow-up. Details of adverse events reported during the 
intervention phase of the study are provided as an 
appendix to a study published by Burn and colleagues.20
Statistical analysis
The analysis was designed to test the hypothesis that 
resistant starch would reduce the development of 
colorectal cancer (the primary outcome) and Lynch 
syndrome cancers (as a secondary outcome). The primary 
endpoint of this analysis was the development of 
colorectal cancer in participants, comparing the incidence 
in those randomly assigned to resistant starch with the 
incidence in those assigned to resistant-starch placebo.
The analysis was based on time to ﬁ rst occurrence of 
colorectal cancer with life-table methods and Cox 
proportional hazards. The life-table analysis used the end 
of follow-up for each participant as (1) the time of ﬁ rst 
colorectal cancer diagnosis, if aﬀ ected, or (2) for those 
unaﬀ ected, the last recorded contact date at which the 
clinical status of the participant was known. Analyses 
also included Cox proportional hazards models to 
estimate sex adjusted hazard ratios (HRs) and 95% CI 
and Kaplan-Meier curves to non-parametrically assess 
the outcome diﬀ erences between the resistant starch and 
resistant-starch placebo interventions. 
We used Poisson regression modelling to estimate 
incidence rate ratios (IRR) for the eﬀ ect of resistant 
starch on the number of primary colorectal cancers 
diagnosed after randomisation, with the exposure time 
starting from randomisation until date of last known 
clinical status. All estimates were adjusted for duration 
of aspirin taken and sex. Analyses were done on an 
intention-to-treat basis (intervention assigned at 
randomisation) and on a per-protocol basis restricting 
analysis to those taking resistant starch for 2 years 
or more.
Since patients with Lynch syndrome are susceptible to 
primary cancers at multiple anatomical sites, a separate 
analysis addressed the eﬀ ect of resistant starch on risk of 
all Lynch syndrome cancers that included all new 
cancers that occurred as a result of Lynch syndrome (ie, 
colorectal cancer, endometrial cancer, ovarian cancer, 
pancreatic cancer, and cancer of the brain, small bowel, 
gall bladder, ureter, stomach, and kidney).24 We also 
compared the incidence of Lynch syndrome excluding 
cancers of the colorectum as a measure of the potential 
extra colonic eﬀ ects of resistant starch. 
Figure 1: Study proﬁ le
463 allocated to resistant starch 455 allocated to resistant-starch 
         placebo
134 excluded
         62 ineligible
         72 eligible but withdrew consent 
               before intervention commenced
463 analysed 455 analysed
1037 participants randomly assigned
937 eligible, commenced intervention, 
         and subject to analysis
19 randomised to aspirin or 
       aspirin placebo only
Resistant starch Resistant-starch placebo
Number of participants 463 455
Sex
Male 208 (44·9%) 193 (42·4%)
Female 255 (55·1%) 262 (57·6%)
Age, years 44·2 (36·0–52·9) 45·3 (36·7–53·4)
Age group, years
21–36 124 (26·8%) 109 (24·0%)
37–45 116 (25·1%) 113 (24·8%)
46–53 114 (24·6%) 118 (25·9%)
54–78 109 (23·5%) 115 (25·3%)
Geographical regions
Northern Europe 212 (45·8%) 198 (43·5%)
UK 133 (28·7%) 118 (25·9%)
Other regions 118 (25·5%) 139 (30·6%)
Long-term follow-up data status
Total
Participants with long follow-up 359 (77·5%) 355 (78·0%)
Participants without long follow-up 104 (22·5%) 100 (22·0%)
With exit colonoscopy*
Participants with long follow-up 301 (84·1%) 318 (86·2%)
Participants without long follow-up 57 (15·9%) 51 (13·8%)
No exit colonoscopy*
Participants with long follow-up 58 (55·2%) 37 (43·0%)
Participants without long follow-up 47 (44·8%) 49 (57·0%)
Data are number, number (%), or median (IQR). *Percentages reﬂ ect the proportion of all participants with or without 
long term follow-up as a percentage of those with exit colonoscopy.
Table 1: Characteristics of study participants 
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All estimated eﬀ ects of resistant starch were adjusted for 
sex and duration of aspirin taken, all p values were two-
sided, and all analyses were done with Stata (version 10).
This study is registered, ISRCTN 59521990.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The contracts associated with the 
donations from manufacturers required that they had 
access to the results before submission with up to 
90 days for assessment. JCM, MM, DTB, and JB had 
access to the raw data. JCM, DTB, and JB took 
responsibility for the decision to submit for publication. 
Results
Of the 937 eligible participants with Lynch syndrome 
who started the study, 463 were randomly assigned to 
receive resistant starch and 455 to receive resistant-starch 
placebo. The remaining 19 participants were randomly 
assigned to the aspirin or aspirin placebo intervention 
only and were excluded from this analysis (ﬁ gure 1; 
appendix). There was no evidence of any interaction 
between the eﬀ ects of aspirin and starch (Mantel-Haenszel 
χ² [1 degree of freedom] 0·02; p=0·9), however, for 
completeness, we report the eﬀ ects of resistant starch 
adjusted for aspirin usage.
More than half of participants were women (table 1). 
Long-term follow-up data were not available for 204 (22%) 
participants. Thus, for 714 participants, we report both 
on-trial information and longer follow-up information, 
whereas for 204 we report on-trial information only. 
Demographic data show that no diﬀ erences occurred 
between those traced and not traced after the trial in this 
follow-up with respect to sex, randomisation category, or 
geographical location (data not shown). At the time of 
this analysis, eight (1%) participants were 10 years or 
longer from randomisation.
Median follow-up was 52·7 months (IQR 28·9–78·4; 
appendix). Since randomisation, 53 individuals—27 of 
those given resistant starch and 26 given resistant-starch 
placebo—developed 61 primary colorectal cancers 
(table 2, appendix). 45 of these patients had colorectal 
cancer detected during long-term follow-up (23 of those 
allocated resistant starch and 22 of those allocated 
resistant-starch placebo; χ² 0·59; p=0·7). The remaining 
eight participants diagnosed with colorectal cancer had 
information from the intervention phase only (ﬁ ve in 
those allocated to resistant starch and three in those 
allocated to resistant-starch placebo [χ² 0·44; p=0·5]). 
Of 746 patients with on-trial data, there were 
25 patients with colorectal cancers who received resistant-
starch placebo and 22 who received resistant starch 
(χ² 0·62, p=0·7). 
For the period after randomisation, the HR for 
colorectal cancer in those randomly assigned to resistant 
starch was 1·40 (95% CI 0·78–2·56; p=0·26) showing no 
evidence for a protective eﬀ ect of resistant starch (table 3, 
ﬁ gure 2). The HR for colorectal cancer without adjusting 
for aspirin duration was similar (1·33, 0·73–2·41). The 
intention-to-treat analysis by the Poisson regression 
model that took into account the eight multiple primary 
participants with colorectal cancer (seven in the resistant-
starch placebo group and one in the resistant-starch 
group) also showed no protective eﬀ ect of resistant starch 
(table 3). There was no signiﬁ cant modiﬁ cation eﬀ ect of 
aspirin taken on the estimated HR for resistant starch 
(p=0·89) and the mean duration of aspirin use was 
similar for both resistant starch (25·0 months [SD 12·9]) 
Resistant starch Resistant-starch 
placebo
Number of participants 463 455
Months on CAPP2 intervention study 24·4 (13·3–28·7) 24·6 (17·3–29·2)
Months since study entry 53·2 (29·4–83·2) 52·4 (28·7–74·6)
Number of participants with ﬁ rst colorectal cancer
Since randomisation 27 26
Within 2 years of randomisation 10 10
More than 2 years from randomisation 17 16
Number of participants with other Lynch syndrome cancers* 
Since randomisation 17 26
Within 2 years of randomisation 6 9
More than 2 years from randomisation 11 17
Number of participants with one or more Lynch syndrome cancers (including colorectal cancer)
Since randomisation 43 51
Within 2 years of randomisation 16 19
More than 2 years from randomisation 27 32
Number of participants with non-Lynch syndrome cancers 22 22
Data are number or median (IQR). *Two participants (one in resistant-starch placebo group and one in resistant starch 
group) had colorectal cancer and another had a Lynch syndrome cancer. These two participants are counted in the 
rows relating to both colorectal cancer and other Lynch syndrome cancers but in the row relating to all Lynch 
syndrome cancers these participants are counted only once.  
Table 2: Duration of study and cancer burden according to intervention group
Hazard ratio* Incidence rate ratio†
HR (95% CI) p value IRR (95% CI) p value
Intention-to-treat analysis
Resistant starch vs 
resistant-starch placebo
1·40 (0·78–2·56) 0·26 1·15 (0·66–2·00) 0·61
Per-protocol analysis
Resistant-starch placebo 1·00 ·· 1·00 ··
<2 years of resistant starch‡ 2·38 (0·98–5·77) 0·05 1·59 (0·69–3·63) 0·27
≥2 years of resistant starch‡ 1·09 (0·55–2·19) 0·80 0·98 (0·51–1·88) 0·95
Cumulative starch dose (units of 
100 resistant starch)
1·01 (0·98–1·04) 0·56 1·00 (0·98–1·03) 0·72
*Cox proportional hazards analysis based on 53 participants with colorectal cancer involving a total of 61 cancer 
diagnoses. †Incidence rate ratio from Poisson regression. ‡The threshold for 2 years intervention was consumption of 
more than 1400 starch packs; rounded down from a 2 year total of 1461 packs to allow for early scheduling of the exit 
colonoscopy, occasional missed dosage, or both. 
Table 3: Cox proportional hazards analysis and Poisson regression for colorectal cancer (adjusted for sex 
and duration of aspirin taken) based only on participants randomly assigned to resistant starch or 
resistant-starch placebo
For the study protocol see 
http://www.capp3.org
See Online for appendix
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and resistant-starch placebo groups (25·0 months [SD 
12·5]). Additionally, a simple comparison of eﬀ ect of 
resistant starch in participants randomly assigned to 
aspirin showed no signiﬁ cant diﬀ erence (HR 1·38, 
95% CI 0·76–2·51).
We re-estimated the potential protective eﬀ ect of 
resistant starch with a per-protocol analysis and obtained 
similar results. For this analysis, we deﬁ ned 2 years 
intervention as consumption of 1400 packs (2×15 g a day); 
consumption was rounded down from a 2-year total 
(1461 packs) to allow for early scheduling of the exit 
colonoscopy, occasional missed dosage, or both. The HR 
for participants taking resistant starch for less than 
2 years was 2·38 (95% CI 0·98–5·77; p=0·05), which 
suggested a possible adverse eﬀ ect of shorter-term 
resistant starch treatment on incidence of colorectal 
cancer (table 3, ﬁ gure 2). By contrast, the HR for 
participants taking resistant starch for 2 years or more 
was 1·09 (0·55–2·19; p=0·80) and the IRR was 0·98 
(0·51–1·88; p=0·95; table 3, ﬁ gure 2). 
A secondary analysis assessed other Lynch syndrome 
cancers (ie, all Lynch syndrome cancers except colorectal 
cancer). Of the participants who developed cancer at a 
Lynch syndrome site other than the colorectum, 17 were 
randomly assigned to resistant starch and 26 to placebo 
(table 2; appendix). The HR for participants randomly 
assigned to resistant starch was 0·72 (95% CI 0·38–
1·35; p=0·30; table 4, appendix) compared with the 
resistant-starch placebo group. Endometrial cancer was 
the most common non-colorectal cancer; 21 participants 
had endometrial cancer of whom ten were randomly 
assigned to resistant starch and 11 to resistant-starch 
placebo (appendix). Of note, no participants assigned to 
resistant starch had pancreatic or small-bowel cancer 
compared with ﬁ ve cases of pancreatic cancer and three 
cases of small-bowel cancer in those randomly assigned 
to resistant-starch placebo. In view of the small 
numbers, this potential protective eﬀ ect could be a 
chance observation. The per-protocol analysis showed 
that the HR for those allocated to resistant starch who 
took treatment for less than 2 years was 0·87 (95% CI 
0·34–2·22; p=0·77) whereas for those taking resistant 
starch for 2 years or more the HR was 0·63 (0·28–1·40; 
p=0·26) with an IRR of 0·56 (0·26–1·23; p=0·15; 
table 4). 
In analyses of all Lynch syndrome cancers including 
colorectal cancer, there was no evidence of a protective 
eﬀ ect for resistant starch in either the per-protocol or 
intention-to-treat populations, nor when analysed by 
duration of treatment (table 5, ﬁ gure 3). Cox proportional 
hazards models analysis by cumulative resistant starch 
consumption showed no evidence of a signiﬁ cant dose–
response eﬀ ect for colorectal cancer (p=0·56), non-
colorectal Lynch syndrome cancers (p=0·21), or Lynch 
syndrome cancers overall (p=0·56; tables 3–5). 
We have published a detailed analysis of the adenomas 
that were reported during the intervention phase of 
the CAPP2 study.20 Where possible, details of adenoma 
development were also gathered by masked investigators 
in the post-intervention period. While incomplete, these 
data on 1068 colonoscopy reports showed no apparent 
eﬀ ect of resistant starch on numbers of participants who 
developed adenomas subsequent to the intervention 
phase (ie, 114 reports of adenomas in each of the 
resistant starch and resistant-starch placebo groups from 
558 and 488 colonoscopies, respectively [p=0·25]). No 
diﬀ erence was seen in the number of colonoscopies in 
participants randomly assigned to resistant starch and 
to the corresponding placebo group (p=0·24; data not 
shown). Additionally, there was no evidence of an eﬀ ect 
of resistant starch treatment on adenomas when the 
analysis was restricted to those on starch treatment for 
2 years or more (p=0·25).
Figure 2: Time to ﬁ rst colorectal cancer in participants randomly assigned to resistant starch versus those 
assigned to resistant-starch placebo
Kaplan-Meier analysis, adjusted for sex (A). Kaplan-Meier analysis restricted to participants who had taken the 
intervention for 2 years or more, adjusted for sex (B). Each point on the plot shows the estimated cumulative 
incidence by years of follow-up together with the corresponding 95% CI. CAPP=Colorectal Adenoma/carcinoma 
Prevention Programme.
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In view of the suggestion that the end product of resistant 
starch fermentation, butyrate, could have more potent 
antineoplastic eﬀ ects on colon-cancer cells with 
dysfunction of the DNA mismatch repair gene MLH1,14 the 
data were analysed according to the underlying mismatch 
repair gene defect and no eﬀ ect was seen (appendix). 
20 (32·8%) of the 61 colorectal cancers diagnosed in 
resistant starch or placebo groups were Dukes stage A, 
25 (41·0%) were Dukes stage B, 12 (19·7%) were Dukes 
stage C and D, and four (6·6%) were unknown (appendix). 
33 (54·1%) tumours were located in the ascending colon, 
transverse colon, and splenic ﬂ exure, six (9·8%) in the 
descending colon, 13 (21·3%) in the sigmoid and rectum, 
and nine (14·8%) were unknown (appendix). No 
signiﬁ cant diﬀ erences in tumour staging (χ² [3 degrees of 
freedom] 6·73; p=0·08) and tumour location (χ² [3 degrees 
of freedom] 0·54; p=0·91) were seen between resistant-
starch and resistant-starch placebo groups.
Discussion
To the best of our knowledge, our report is the ﬁ rst 
randomised trial to assess the eﬀ ectiveness of dietary-
ﬁ bre treatment (provided as a resistant-starch 
supplement) on carcinoma in human beings (panel). A 
recent meta-analysis of 21 prospective observational 
studies showed a signiﬁ cant protective eﬀ ect of dietary-
ﬁ bre int ake against colorectal cancer (RR per 10 g a day 
increase 0·90, 95% CI 0·86–0·94).2 An earlier pooled 
analysis of prospective cohort studies25 showed no eﬀ ect 
of dietary ﬁ bre on risk of colorectal cancer after adjusting 
for other dietary factors but that analysis included fewer 
studies and fewer cases of colorectal cancer and had a 
narrower geographical reach compared with the recent 
systematic review and meta-analysis by Aune and 
colleagues.2 Previous randomised trials with occurrence 
of further adenoma as an outcome have not detected any 
beneﬁ t of increased intake of dietary ﬁ bre. These 
included studies with supplements of ispaghula husk26 
and cereal ﬁ bre27 and studies in which participants were 
counselled to increase intake of ﬁ bre-rich foods.28,29 The 
lack of beneﬁ t associated with increased intake of dietary 
ﬁ bre in these studies led to questions about the 
usefulness of adenoma recurrence as the primary 
surrogate endpoint in colorectal cancer chemoprevention 
research.30,31 The CAPP2 study has provided experimental 
support for this scepticism since we reported no eﬀ ect of 
aspirin treatment on neoplasia (principally adenomas) 
during the intervention phase of the study20 but 
signiﬁ cant protection against carcinoma in longer-term 
follow-up.21
A limitation of the present study is that lack of 
resources has restricted longer-term follow-up of all 
CAPP2 participants. This loss to follow-up was 
concentrated in centres that had insuﬃ  cient staﬀ 
resources to allow long-term follow-up of all the study 
participants. Since randomisation to treatment was 
stratiﬁ ed within geographical location, it is unlikely that 
any systematic bias exists in loss to follow-up. We 
examined the numbers of colorectal cancer that occurred 
during the intervention phase of the study and the follow-
up phase, separately, and found no  evidence to suggest 
that loss of cancer data due to failure to follow-up patients 
was diﬀ erent between those randomly assigned to 
resistant starch or to placebo; there was also no eﬀ ect of 
duration of taking resistant starch. Thus we conclude 
that there was no evidence for a protective eﬀ ect of 
resistant starch even in those participants who were most 
compliant. We do not have data for intake of dietary ﬁ bre 
for our study participants. However, geographical 
location is a crude surrogate for dietary and other lifestyle 
exposures. We randomised participants to treatment 
within geographical regions. We found that adjusting 
our analysis for region as well as for sex and aspirin 
duration gave a hazard ratio of 1·44 (95% CI 0·79–2·62), 
Hazard ratio* Incidence rate ratio†
HR (95% CI) p value IRR (95% CI) p value
Intention-to-treat analysis
Resistant starch vs 
resistant-starch placebo
0·72 (0·38–1·35) 0·30 0·71 (0·38–1·32) 0·28
Per-protocol analysis
Resistant-starch placebo 1·00 ·· 1·00 ··
<2 years of resistant starch‡ 0·87 (0·34–2·22) 0·77 1·02 (0·42–2·51) 0·96
≥2 years of resistant starch‡ 0·63 (0·28–1·40) 0·26 0·56 (0·26–1·23) 0·15
Cumulative starch dose (units of 
100 resistant starch)
0·98 (0·94–1·01) 0·21 0·98 (0·94–1·01) 0·17
*Cox proportional hazards analysis based on 43 participants with non-colorectal Lynch syndrome cancers involving a 
total of 46 cancer diagnoses. †Incidence rate ratio from Poisson regression. ‡The threshold for 2 years intervention 
was consumption of more than 1400 starch packs; rounded down from a 2-year total of 1461 packs to allow for early 
scheduling of the exit colonoscopy, occasional missed dosage, or both. 
Table 4: Cox proportional hazards analysis and Poisson regression for non-colorectal Lynch syndrome 
cancers (adjusted for sex and duration of aspirin taken) based only on participants randomly assigned to 
resistant starch or resistant-starch placebo
Hazard ratio* Incidence rate ratio†
HR (95% CI) p value IRR (95% CI) p value
Intention-to-treat analysis
Resistant starch vs 
resistant-starch placebo
1·02 (0·66–1·57) 0·94 0·93 (0·62–1·39) 0·72
Per-protocol analysis
Resistant-starch placebo 1·00 ·· 1·00 ··
<2 years of resistant starch‡ 1·45 (0·77–2·73) 0·26 1·29 (0·70–2·36) 0·41
≥2 years of resistant starch‡ 0·83 (0·49–1·40) 0·48 0·77 (0·47–1·26) 0·30
Cumulative starch dose (units of 
100 resistant starch)
0·99 (0·97–1·02) 0·56 0·99 (0·97–1·01) 0·52
*Cox proportional hazards analysis based on 94 participants with Lynch syndrome cancers involving a total of 
107 cancer diagnoses. †Incidence rate ratio from Poisson regression. ‡The threshold for 2 years intervention was 
consumption of more than 1400 starch packs; rounded down from a 2-year total of 1461 packs to allow for early 
scheduling of the exit colonoscopy, occasional missed dosage, or both.
Table 5: Cox proportional hazards analysis and Poisson regression for all Lynch syndrome cancers 
(adjusted for sex and duration of aspirin taken) based only on those randomly assigned to resistant 
starch or resistant-starch placebo
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which suggests that lifestyle factors do not play a major 
role in modifying the response to resistant starch.
A strength of the present study was that we used 
patients with Lynch syndrome due to a genetic defect in 
DNA mismatch repair as a sensitive model, which can 
show the eﬀ ectiveness of chemoprevention agents 
(aspirin) on colorectal cancer and carcinoma at other 
sites.21 The intention-to-treat analysis showed no eﬀ ect of 
resistant starch on colorectal cancer or on other Lynch 
syndrome cancers. Per-protocol analysis suggested higher 
risk of colorectal cancer in those taking resistant starch 
for less than 2 years, but this eﬀ ect is probably due to 
chance observation because no eﬀ ect was seen in 
participants taking resistant starch for 2 years or more 
(table 3). We cannot exclude the possibility that resistant 
starch could have a small positive eﬀ ect that we did not 
have the power to detect. A recent meta-analysis of the 
protective eﬀ ects of dietary ﬁ bre against colorectal cancer 
suggests an estimated 10% reduction in colorectal-cancer 
risk.2 The 30 g a day source of resistant starch used in the 
CAPP2 study provides 13·2 g resistant starch, which 
reaches the large bowel and is classed as dietary ﬁ bre.20 
On this basis, the resistant starch might have reduced 
colorectal risk by 8–18%, which is within the 95% CI of 
our intention-to-treat analysis (table 2). This lack of 
detectable eﬀ ect of resistant starch on risk of colorectal 
cancer contrasts with the weight of observational studies 
showing a protective eﬀ ect of higher intakes of dietary 
ﬁ bre but is consistent with the ﬁ ndings from randomised 
trials26–29 of increased intake of dietary ﬁ bre with 
occurrence of new colorectal adenoma as surrogate 
outcome. The eﬀ ects of resistant starch in carriers of 
hereditary colorectal cancer could be diﬀ erent from those 
in the general population and this remains to be tested. 
Additionally, observational studies might be aﬀ ected by 
confounding or the apparent protection aﬀ orded by 
higher intakes of dietary ﬁ bre could reﬂ ect the health 
beneﬁ t of the dietary patterns (or whole lifestyles) adopted 
by such consumers rather than the speciﬁ c antineoplastic 
eﬀ ects of the carbohydrates measured as dietary ﬁ bre. 
Evidence shows that the individual carbohydrates (and 
associated food components) quantiﬁ ed as dietary ﬁ bre 
have highly characteristic physicochemical properties and 
very diﬀ erent eﬀ ects on both fermentation in the large 
bowel and on function of the bowel mucosa.3 As a 
consequence, emulation of the eﬀ ects of naturally 
occurring dietary ﬁ bre in plant-rich diets by a single type 
of polysaccharide, such as resistant starch, is unlikely.1,32 
We are under taking several secondary analyses, including 
investi gation of eﬀ ects of smoking behaviour and of 
adiposity on risk of colorectal cancer in patients with 
Lynch syndrome in the CAPP2 study, which will be 
reported elsewhere.  
In conclusion, we found no evidence that supple-
mentation with 30 g a day of resistant starch aﬀ ected 
development of colorectal cancer in carriers of 
hereditary colorectal cancer, although eﬀ ects in the 
general population remain to be tested. Our study 
shows that supplementation with resistant starch does 
not emulate the apparently protective eﬀ ect against 
colorectal cancer of diets rich in dietary ﬁ bre, which has 
been shown in many, but not all, observational studies. 
From a public health perspective, eating more of a 
variety of food rich in dietary ﬁ bre including 
wholegrains, vegetables, fruits, and pulses is a 
preferable strategy for reducing cancer risk. 
Panel: Research in context
Systematic review
We searched PubMed for articles on use of dietary ﬁ bre or resistant starch as a bowel 
cancer, hereditary colorectal cancer, and Lynch syndrome chemopreventive agent 
published up to Feb 10, 2012. Our search terms were “colorectal cancer” OR “bowel cancer” 
AND “prevention” AND “ﬁ bre” with the search restricted to randomised trials. Additionally, 
we replaced “ﬁ bre” with “ﬁ ber” or with “starch”. Systematic reviews by other investigators 
had revealed compelling evidence for the protective eﬀ ect of dietary ﬁ bre against sporadic 
bowel cancer in observational studies. Resistant starch, a dietary starch fraction that is not 
digested in the small bowel, is a speciﬁ c form of dietary ﬁ bre. Our search of published 
works showed that no previous randomised trials have tested the eﬃ  cacy of resistant 
starch in patients with Lynch syndrome with cancer as the primary endpoint. 
Interpretation
We found no evidence that dietary supplementation with resistant starch aﬀ ected risk of 
colorectal cancer in carriers of hereditary colorectal cancer. The lack of eﬀ ect of resistant 
starch shows that this supplement does not emulate the apparently protective eﬀ ect of 
diets rich in dietary ﬁ bre against colorectal cancer, at least in patients with Lynch 
syndrome. The eﬀ ect of resistant starch on risk of bowel cancer in the general population 
remains to be tested.
Figure 3: Time to ﬁ rst Lynch syndrome cancer in participants randomly assigned to resistant starch versus 
those assigned to resistant-starch placebo
Kaplan-Meier analysis was restricted to participants who had taken the intervention for 2 years or more and the 
analysis was adjusted for sex. Each point on the plot shows the estimated cumulative incidence by years of 
follow-up together with the corresponding 95% CI. CAPP=Colorectal Adenoma/carcinoma Prevention Programme.
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